Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

2014 San Antonio Breast Cancer Symposium

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05, “Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709,” presented by William M. Sikov, MD.

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Oct

Today In Oncology

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Related Videos

Harry D. Bear, MD, PhD, on the NSABP B-40 Study in HER2-Negative Breast Cancer

Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial

Lisa A. Carey, MD, on the TNT Trial

Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

The Molecular Watchman Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers

Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases

Replacing Intensive Chemotherapy With Blinatumomab Improves Outcomes in High-Risk Pediatric Acute Lymphoblastic Leukemia

Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis

Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study